EA Pharma
EA Pharma is a specialty pharmaceutical company focusing on gastrointestinal diseases. It was established in April 2016 through the integration of the gastrointestinal disease businesses of Eisai Group and Ajinomoto Group, leveraging research, development, production, logistics, sales, and marketing to create innovative solutions. The company aims to contribute to patients and their families by developing advanced new drugs and providing comprehensive support for gastrointestinal health.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
US-11311508-B2
View Details
Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
US-11311508-B2
View DetailsProducts
Enteral / clinical nutrition formulations
Oral enteral nutrition products formulated for nutritional management and clinical use, with supporting flavour/accessory options.
Oral electrolyte bowel preparation formulations
Oral bowel-cleansing solutions developed for use prior to endoscopic procedures, supplied with patient guidance materials.
Therapeutics for inflammatory bowel disease and chronic constipation (marketed and pipeline)
Portfolio and development-stage therapeutics (oral and topical formulations) targeting ulcerative colitis, Crohn's disease and chronic constipation.
Small-molecule and mechanism-targeted investigational agents (clinical pipeline)
Investigational small molecules and mechanism-targeted agents in clinical development for gastrointestinal indications, including oral modulators and integrin-targeting agents.
Enteral / clinical nutrition formulations
Oral enteral nutrition products formulated for nutritional management and clinical use, with supporting flavour/accessory options.
Oral electrolyte bowel preparation formulations
Oral bowel-cleansing solutions developed for use prior to endoscopic procedures, supplied with patient guidance materials.
Therapeutics for inflammatory bowel disease and chronic constipation (marketed and pipeline)
Portfolio and development-stage therapeutics (oral and topical formulations) targeting ulcerative colitis, Crohn's disease and chronic constipation.
Small-molecule and mechanism-targeted investigational agents (clinical pipeline)
Investigational small molecules and mechanism-targeted agents in clinical development for gastrointestinal indications, including oral modulators and integrin-targeting agents.
Services
AI-based automated response system that provides general product and disease information to registered medical professionals.
Web-based ordering system for clinical nutrition and bowel-preparation accessories available to medical institutions.
Telephone and email-based enquiry handling and product consultation services for patients and healthcare professionals.
AI-based automated response system that provides general product and disease information to registered medical professionals.
Web-based ordering system for clinical nutrition and bowel-preparation accessories available to medical institutions.
Telephone and email-based enquiry handling and product consultation services for patients and healthcare professionals.
Expertise Areas
- Gastroenterology-focused drug development
- Clinical trial management (including early-phase studies)
- Enteral and clinical nutrition formulation
- Electrolyte bowel preparation formulations
Key Technologies
- AI-driven target discovery
- Mobile health applications
- AI chatbot / natural language processing for medical information
- Clinical trial conduct and data reporting
News & Updates
Notification regarding access issues on June 13, 2025.
Announcement of organizational restructuring and personnel changes as of June 25, 2025.
Announcement of executive personnel changes as of June 25, 2025.
Release of a company overview video.
A video providing an overview of EA Pharma's activities.
EA Pharma received sustainability certification for its environmental and social initiatives.
Notification regarding access issues on June 13, 2025.
Announcement of organizational restructuring and personnel changes as of June 25, 2025.
Announcement of executive personnel changes as of June 25, 2025.
Release of a company overview video.
A video providing an overview of EA Pharma's activities.
EA Pharma received sustainability certification for its environmental and social initiatives.